HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Raises Price Target to $40
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Douglas Tsao maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $22 to $40.
HC Wainwright & Co. analyst Douglas Tsao maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $22 to $40.